Novartis COVID-19 Therapy Could Overcome Escape Variant Problem

Protein Therapeutic Enters Pivotal Trial

 
• By Andrew McConaghie
  
Novartis
Novartis is using a novel Phase II/III trial design to produce fast results in patients with early stage COVID-19 infections.
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip